DAPAGLIFLOZIN MODULATES ADROPIN SERUM LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC HEART FAILURE

被引：0
|
作者：
Berezin, Alexander [1 ]
Fushtey, Ivan M. [2 ]
Berezin, Alexander A. [2 ]
机构：
[1] State Med Univ, Dept Internal Med, Zaporozhe, Ukraine
[2] Med Acad Postgrad Educ, Dept Internal Med, Zaporozhe, Ukraine
来源：
JOURNAL OF HYPERTENSION | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
下载
收藏
页码：E100 / E100
页数：1
相关论文
共 50 条
  • [1] The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus
    Berezin, A.
    Fuschtey, I. M.
    Berezin, A. A.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [2] The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure
    Berezin, Alexander A.
    Obradovic, Zeljko
    Fushtey, Ivan M.
    Berezina, Tetiana A.
    Novikov, Evgen V.
    Schmidbauer, Lukas
    Lichtenauer, Michael
    Berezin, Alexander E.
    BIOMEDICINES, 2023, 11 (02)
  • [3] Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure
    Berezina, Tetiana A.
    Obradovic, Zeljko
    Boxhammer, Elke
    Berezin, Alexander A. A.
    Lichtenauer, Michael
    Berezin, Alexander E. E.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [4] Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides
    Berezina, Tetiana A.
    Berezin, Oleksandr O.
    Hoppe, Uta C.
    Lichtenauer, Michael
    Berezin, Alexander E.
    DIAGNOSTICS, 2024, 14 (16)
  • [5] Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus
    Berg, D.
    Wiviott, S.
    Scirica, B.
    Gurmu, Y.
    Mosenzon, O.
    Murphy, S.
    Bhatt, D.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Johansson, P.
    Langkilde, A.
    Raz, I.
    Braunwald, E.
    Sabatine, M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 153 - 153
  • [6] Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and concomitant heart failure
    Kosiborod, M.
    Gause-Nilsson, I.
    Sonesson, C.
    Johnsson, E.
    DIABETOLOGIA, 2015, 58 : S368 - S368
  • [7] Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
    Kato, Eri T.
    Silverman, Michael G.
    Mosenzon, Ofri
    Zelniker, Thomas A.
    Cahn, Avivit
    Furtado, Remo H. M.
    Kuder, Julia
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Bonaca, Marc P.
    Ruff, Christian T.
    Desai, Akshay S.
    Goto, Shinya
    Johansson, Peter A.
    Gause-Nilsson, Ingrid
    Johanson, Per
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2019, 139 (22) : 2528 - 2536
  • [8] Effects of dapagliflozin on cardiac function indexes and serum MCP-1 levels in patients with Type 2 diabetes mellitus complicated with heart failure
    Zhang, Xianpei
    Yang, Yang
    Xiao, Weizhe
    Liu, Jing
    Zhang, Xiaojun
    Chen, Ke
    Xiao, Wenliang
    Wang, Chuanqiang
    BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, 2023, 40 (04) : 3963 - 3975
  • [9] DECREASED SERUM LEVELS OF IRISIN PREDICTED HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Berezin, Alexander
    Fushtey, Ivan
    Berezin, Alexander
    JOURNAL OF HYPERTENSION, 2023, 41 : E101 - E101
  • [10] Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus
    Berezin, Alexander A.
    Fushtey, Ivan M.
    Pavlov, Sergii, V
    Berezin, Alexander E.
    MOLECULAR BIOMEDICINE, 2022, 3 (01):
12345